Moreover, the FDA also accelerated approval of the anti-PD-1 antibody pembrolizumab as monotherapy and a combination of nivolumab (another anti-PD-1 antibody) and ipilimumab (an anti-ctLA4 antibody) for second-line treatment of advanced liver cancer, based on efficacy data from early trials. The gene discussed is CTLA4; the disease is liver cancer.